Immunomodulation for unexplained recurrent implantation failure: where are we now?
Reproduction · 2023
DOI: 10.1530/rep-22-0150 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Reproduction, 2023. Verfasst von Geneviève Genest und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Allergy and Immunology, McGill University, Montreal Quebec, Canada. Hauptthemen laut MEDLINE: Embryo Implantation, Embryo Transfer. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 229 Literaturangaben.
Abstract (Originalsprache)
In brief Immune dysfunction may contribute to or cause recurrent implantation failure. This article summarizes normal and pathologic immune responses at implantation and critically appraises currently used immunomodulatory therapies. Abstract Recurrent implantation failure (RIF) may be defined as the absence of pregnancy despite the transfer of ≥3 good-quality blastocysts and is unexplained in up to 50% of cases. There are currently no effective treatments for patients with unexplained RIF. Since the maternal immune system is intricately involved in mediating endometrial receptivity and embryo implantation, both insufficient and excessive endometrial inflammatory responses during the window of implantation are proposed to lead to implantation failure. Recent strategies to improve conception rates in RIF patients have focused on modulating maternal immune responses at implantation, through either promoting or suppressing inflammation. Unfortunately, there are no validated, readily available diagnostic tests to confirm immune-mediated RIF. As such, immune therapies are often started empirically without robust evidence as to their efficacy. Like other chronic diseases, patient selection for immunomodulatory therapy is crucial, and personalized medicine for RIF patients is emerging. As the literature on the subject is heterogenous and rapidly evolving, we aim to summarize the potential efficacy, mechanisms of actions and side effects of select therapies for the practicing clinician.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Allergy and Immunology, McGill University, Montreal Quebec, Canada.
- Department of Gynaecology, University of Montreal, Montreal, Quebec, Canada.
- McGill University Health Centre Reproductive Centre, Montreal, Quebec, Canada.
- Tripod Medical, Toronto, Ontario.
- Department of Obstetrics and Gynecology, McGill University, McGill University Health Centre, Montreal, Quebec, Canada.
- Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montréal, Quebec, Canada.
ORCID-Profile: Geneviève Genest, Einav Kadour-Peero
Zitieren
APA
Genest, G., Banjar, S., Almasri, W., Beauchamp, C., Benoit, J., Buckett, W., Dzineku, F., Gold, P., Dahan, M. H., Jamal, W., Jacques Kadoch, I., Kadour-Peero, E., Lapensée, L., Miron, P., Shaulov, T., Sylvestre, C., Tulandi, T., Mazer, B. D., Laskin, C. A., & Mahutte, N. (2023). Immunomodulation for unexplained recurrent implantation failure: where are we now?. Reproduction. https://doi.org/10.1530/rep-22-0150
Vancouver
Genest G, Banjar S, Almasri W, Beauchamp C, Benoit J, Buckett W, et al. Immunomodulation for unexplained recurrent implantation failure: where are we now?. Reproduction. 2023. doi:10.1530/rep-22-0150
BibTeX
@article{Genest2023,
author = {Genest, Geneviève and Banjar, Shorooq and Almasri, Walaa and Beauchamp, Coralie and Benoit, Joanne and Buckett, William and Dzineku, Frederick and Gold, Phil and Dahan, Michael H and Jamal, Wael and Jacques Kadoch, Isaac and Kadour-Peero, Einav and Lapensée, Louise and Miron, Pierre and Shaulov, Talya and Sylvestre, Camille and Tulandi, Togas and Mazer, Bruce D and Laskin, Carl A and Mahutte, Neal},
title = {Immunomodulation for unexplained recurrent implantation failure: where are we now?},
journal = {Reproduction},
year = {2023},
doi = {10.1530/rep-22-0150}
}
EUVIMED